Microscopic Polyangiitis (MPA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Microscopic Polyangiitis (MPA) Market Outlook

Thelansis’s “Microscopic Polyangiitis (MPA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Microscopic Polyangiitis (MPA)   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Microscopic Polyangiitis (MPA) Overview

Microscopic polyangiitis (MPA) is a small vessel vasculitis associated with antineutrophil cytoplasmic antibodies (ANCA). It primarily affects the kidneys, lungs, and peripheral nerves, although muscle involvement with myalgia is rare and typically diagnosed through muscle biopsy specimens showing necrotizing vasculitis. ANCA is present in only 70% of MPA cases at diagnosis, and most instances of limited MPA lack ANCA altogether. This suggests the involvement of other factors in its development, including:

1. Infectious Causes: There is substantial overlap in the clinical presentation of infectious diseases and MPA, leading to this association. Chronic nasal carriage of Staphylococcus aureus has been implicated in relapsing granulomatosis with polyangiitis (GPA).
2. Drugs: Several drugs, such as hydralazine, thionamides, sulfasalazine, and minocycline, have been linked to the occurrence of ANCA-associated vasculitis.
3. Genetic Factors: genes like HLA-DP, HLA-DR3, and alpha-1 antitrypsin contribute to the pathogenesis of ANCA-associated vasculitides.

MPA has also been associated with silica exposure, which can induce autoimmunity in individuals with genetic predispositions. Microscopic Polyangiitis (MPA) can affect individuals of all age groups but typically develops around age 50. It can affect both genders, with men potentially being more susceptible. Although more common among Caucasians, MPA can affect people of any race or ethnic background.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Microscopic Polyangiitis (MPA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034